Tyrphostin AG 494 is primarily used as a selective inhibitor of receptor tyrosine kinases, particularly targeting the epidermal growth factor receptor (EGFR) pathway. It is widely applied in biomedical research to study signal transduction mechanisms involved in cell proliferation, differentiation, and apoptosis. Due to its ability to block tyrosine kinase activity, it serves as a valuable tool in cancer research, especially in experiments aimed at understanding tumor growth and developing targeted therapies. It has also been used in studies related to inflammation and autoimmune diseases, where aberrant kinase signaling plays a role. Its application extends to in vitro models where modulation of phosphorylation-dependent pathways is required to dissect molecular mechanisms.